Abstract: A positive electrode active material for a lithium secondary battery has secondary micro particles having an average particle size (D50) of 1 to 10 ?m formed by agglomeration of primary macro particles having an average particle size (D50) of 0.5 to 3 ?m and a lithium-M oxide coating layer on all or part of a surface, wherein M is at least one selected from the group consisting of boron, cobalt, manganese and magnesium. The secondary macro particles have an average particle size (D50) of 5 to 20 ?m formed by agglomeration of primary micro particles having a smaller average particle size (D50) than the primary macro particles. The primary macro particles and the primary micro particles are represented by LiaNi1?b?c?dCobMncQdO2+?, wherein 1.0?a?1.5, 0<b<0.2, 0<c<0.2, 0?d?0.1, 0<b+c+d?0.2, ?0.1???1.0, and Q is at least one type of metal selected from the group consisting of Al, Mg, V, Ti and Zr.

Abstract: A positive electrode active material for a lithium secondary battery has a mixture of microparticles having a predetermined average particle size (D50) and macroparticles having a larger average particle size (D50) than the microparticles. The microparticles have the average particle size (D50) of 1 to 10 ?m and are at least one selected from the group consisting of particles having a carbon material coating layer on all or part of a surface of primary macroparticles having an average particle size (D50) of 1 ?m or more, particles having a carbon material coating layer on all or part of a surface of secondary particles formed by agglomeration of the primary macroparticles, and a mixture thereof. The macroparticles are secondary particles having an average particle size (D50) of 5 to 20 ?m formed by agglomeration of primary microparticles having a smaller average particle size (D50) than the primary macroparticles.

Abstract: A positive electrode active material for a secondary battery which includes a nickel-based lithium composite transition metal oxide including nickel (Ni), wherein the lithium composite transition metal oxide satisfies Equation 1 and Equation 2 below 80 nm?crystallite sizeFWHM?150 nm??[Equation 1] ?size(|crystallite sizeIB?crystallite sizeFWHM|)?20??[Equation 2] wherein, in Equation 1 and Equation 2, crystallite sizeFWHM is a crystallite size obtained by calculating from X-ray diffraction (XRD) data using a full width at half maximum (FWHM) method, and crystallite sizeIB is a crystallite size obtained by calculating from XRD data using an integral breadth (IB) method.

Abstract: According to various example embodiment of the present disclosure, a method of sharing item information by an electronic apparatus includes acquiring a request for link information related to at least one item from a user, acquiring first selection information related to an attribute of the link information, and providing link information on a first page including information related to the at least one item based on the request for the link information and the first selection information, in which the link information may include information related to the attribute.

Abstract: According to one aspect of the present invention, there is provided a method for managing a medical information platform using a blockchain, the method comprising the steps of: dynamically calculating an exchange ratio between tokens and points, with reference to at least one of an amount of points that a user intends to exchange for tokens on a medical information platform, an amount of tokens that the user intends to exchange for points on the medical information platform, an amount of tokens present in a token pool managed by the medical information platform, and an amount of points previously exchanged for tokens on the medical information platform; and providing the user with the tokens or points exchanged with reference to the calculated exchange ratio.

Abstract: The present invention provides a chimeric antigen receptor and natural killer cells expressing the same, and particularly, a chimeric antigen receptor (CAR) which includes an intracellular signaling domain including the whole or a portion of an OX40 ligand (CD252), thereby having excellent effects of increasing anticancer activity of immune cells, and immune cells expressing the same.

Abstract: An information providing method of an electronic apparatus according to various example embodiments may include obtaining information on at least one item, identifying brand membership-related information corresponding to the at least one item, and providing at least part of the brand membership-related information based on a specified condition. In addition, other example embodiments are possible.

Abstract: According to various example embodiment of the present disclosure, a method of sharing item information by an electronic apparatus includes acquiring a request for link information related to at least one item from a user, acquiring first selection information related to an attribute of the link information, and providing link information on a first page including information related to the at least one item based on the request for the link information and the first selection information, in which the link information may include information related to the attribute.

Abstract: According to various example embodiment of the present disclosure, a method of sharing item information by an electronic apparatus includes acquiring a request for link information related to at least one item from a user, acquiring first selection information related to an attribute of the link information, and providing link information on a first page including information related to the at least one item based on the request for the link information and the first selection information, in which the link information may include information related to the attribute.

Abstract: According to one aspect of the present invention, there is provided a method for supporting non-face-to-face authentication in a blockchain network, the method comprising the steps of: providing an authenticatee node with authentication result information generated as face-to-face authentication for personal information of an authenticatee is performed by at least one authenticator node in a blockchain network, and matching and recording non-invertible operation information on at least a part of the authentication result information to an account associated with the authenticatee in the blockchain network; and when a request for non-face-to-face authentication of the authenticatee is made by an authentication requester node, verifying validity of information for authentication, which is provided from the authentication requester node for the request for the non-face-to-face authentication of the authenticatee, on the basis of the non-invertible operation information recorded in the blockchain network.

Abstract: According to one aspect of the present invention, there is provided a method for providing a blockchain-based medical information platform, the method comprising the steps of: managing data input/output between a core layer consisting of a distributed database for storing encrypted medical information and an application layer for providing an application program utilizing the medical information, with reference to information stored on a blockchain; and providing a smart contract for managing at least one of information on tokens or points, information on user accounts, and information on a location where the medical information is stored, with reference to the information stored on the blockchain.

Abstract: According to one aspect of the present invention, there is provided a method for managing a medical information platform using a blockchain, the method comprising the steps of: dynamically calculating an exchange ratio between tokens and points, with reference to at least one of an amount of points that a user intends to exchange for tokens on a medical information platform, an amount of tokens that the user intends to exchange for points on the medical information platform, an amount of tokens present in a token pool managed by the medical information platform, and an amount of points previously exchanged for tokens on the medical information platform; and providing the user with the tokens or points exchanged with reference to the calculated exchange ratio.

Abstract: The present invention provides a chimeric antigen receptor and natural killer cells expressing the same, and particularly, a chimeric antigen receptor (CAR) which includes an intracellular signaling domain including the whole or a portion of an OX40 ligand (CD252), thereby having excellent effects of increasing anticancer activity of immune cells, and immune cells expressing the same.

Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.

Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.